Bio-Technology General Euflexxa 1% Sodium Hyaluronate

Country: Singapore

Language: English

Source: HSA (Health Sciences Authority)

Available from:

FERRING PHARMACEUTICALS PRIVATE LIMITED

Class:

Class D medical device

Manufactured by:

Bio-Technology General (Israel) Ltd.

Therapeutic area:

Orthopaedics

Therapeutic indications:

EUFLEXXA is indicated for the treatment of pain caused by osteoarthritis of the knee, hip, temporomandibular, carpometacarpal, shoulder and ankle joints. EUFLEXXA aids in lubrication of the joint, allows for greater mobility and flexibility of the treated joint, and reduces pain in the affected joint.

Product summary:

Device System Info:[Sterile Medical Device], EUFLEXXA is packed in a single-use, aseptically-filled disposable sterile 2.25 ml syringe (nominal volume) containing either 1 ml or 2 ml of 1% microbial fermentation-derived NaHA in phosphate-buffered saline; Models: Euflexxa 1% Sodium Hyaluronate - 3 x 2ml, Euflexxa 1% Sodium Hyaluronate - 1 x 2ml

Authorization date:

2017-04-28